Jacobson 2008.

Methods	Randomized, double‐blind, placebo‐controlled, dose‐escalating, phase 1b study Randomization: method not specified Allocation concealment: unclear Blinding: the objects that were blinded to were not mentioned Maximum follow‐up: 58 days
Participants	HIV‐infected adults Subjects were ≧ 18 years of age with HIV‐1 RNA levels 5000 ≧ copies/mL, only CCR5‐tropic (R5) HIV‐1 detectable, CD4+ cell counts ≧ 250 cells/μL with no documented nadir ≧200/μL, and no antiretroviral therapy for ≧ 3 months
Interventions	Single IV doses of 0.5 mg/kg (N = 10) Single IV doses of 2 mg/kg (N = 10) Single IV doses of 5 mg/kg (N = 10) Placebo (N = 9)
Outcomes	Antiviral effects (Change in HIV‐1 RNA level from baseline, log10 copies/mL; the proportion of subjects with ≧1 log10 copies/mL decrease in HIV RNA level; the proportion of subjects with < 400 HIV‐1 RNA copies/mL; change in CD4 cell count on day 8, cells/μL) Safety (adverse events): headache, lymphadenopathy, diarrhoea and fatigue
Notes	Potential conflicts of interest: some authors are current or past employees of Progenics Pharmaceuticals and may hold stock or stock options in the company Financial support: National Institutes of Health (Public Health Service grant AI066329)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not specified
Allocation concealment (selection bias)	Unclear risk	This article did not mention
Selective reporting (reporting bias)	Unclear risk	Unclear
Other bias	Unclear risk	Unclear
Blinding	Unclear risk	Blinding: the objects that were blinded to were not mentioned
Incomplete outcome data addressed	Unclear risk	Unclear